Skip to main content
Diana I. Brixner

Diana I. Brixner, RPh, PhD, FAMCP

Languages spoken: English, German

Academic Information

Departments Primary - Pharmacotherapy , Adjunct - Pediatrics

Divisions: Clinical Pharmacology

Currently, I am a Professor in the Department of Pharmacotherapy, Adjunct Professor in the Department of Population Health Sciences and Pediatrics in the Divisions of Health Systems Innovation Research and Clinical Pharmacology and Executive Director of the Pharmacotherapy Outcomes Research Center at the University of Utah. My research focus is on the design, conduct, and communication of pharmacoeconomic and outcomes research studies to demonstrate the value of pharmaceutical and related therapies from the perspective of the private and public payer. I am also a Research Associate at the Institute of Public Health, Medical Decision Making and Health Technology Assessment in the Department of Public Health and Health Technology Assessment at UMIT - University for Health Sciences, Medical Informatics and Technology in Hall i.T., Austria. This appointment supports my international collaborations in oncology research, personalized medicine and value assessment. During my career, I have published over 150 articles in peer-reviewed journals, authored three book chapters, have one issued patent, and have been an invited speaker at a variety of national and international professional meetings. I am a founding member, served on the Executive Board, as well as the Health Policy and Science Council and am a past president of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). In addition, I am a long-standing member and past president of the Academy of Managed Care Pharmacy (AMCP), currently serve as a Director on the Board of the AMCP Biologics & Biosimilars Collective Intelligence Consortium (BBCIC), and have been named as a fellow of the Academy.

Education History

Other Training University of Health Sciences, Medical Informatics and Technology
University of Health Sciences, Medical Informatics and Technology (UMIT)
Certification University of Health Sciences, Medical Informatics and Technology
University of Utah
Undergraduate University of Rhode Island

Selected Publications

Journal Article

  1. Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervari A, Brixner DI, Siebert U (In Press). Systematic overview of cost-effectiveness thresholds in ten countries across four continents with a special focus on personalized cancer medicine. (Epub ahead of print) Per Med.
  2. Hawkes JE, Mittal M, Davis M, Brixner D (2019). Impact of Online Prescription Management Systems on Biologic Treatment Initiation. Adv Ther, 36(8), 2021-2033. (Read full article)
  3. Frost N, Freeman J, Brixner D, Mort J, Clem J, Ngorsuraches S (2019). Patients' preferences and willingness-to-pay for disease-modifying therapies. Mult Scler Relat Disord, 35, 55-60. (Read full article)
  4. Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM (2019). Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm, 25(7), 770-779. (Read full article)
  5. Saverno K, Neu, G, Schmidt S, Wolf D, Conrads-Frank A, Jahn B, Sroczynski G, Brixner, DI (10/28/2013). Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia. Leuk Lymphoma.
  6. Dhamane AD, Martin BC, Brixner DI, Hudson TJ, Said Q (2013). Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract, 19(5), 360-74. (Read full article)
  7. Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI (March 1, 2013). Association Between Second-generation Antipsychotics and Changes in Body Mass Index in Adolescents. J Adolesc Health, 52(3), 336-43.
  8. Brixner DI, Oderda GM, Nickman NA, Beveridge R, Jorgenson JA (2006). Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices. J Natl Compr Canc Netw, 4(3), 197-208. (Read full article)
  9. Trost LF 3rd, Wender RC, Suter CC, Rosenberg JH, Brixner DI, Von Worley AM, Gunter MJ, National Epilepsy Management Panel (2005). Management of epilepsy in adults. Diagnosis guidelines. Postgrad Med, 118(6), 22-6. (Read full article)
  10. Brixner DI, Oderda GM, Nickman NA, Servatius D, Lambert A, Bancroft F, Bretzel R, Beveridge R, Vermulen L, Lentz S (2005). Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community-based oncology practices. . J Natl Compr Canc Netw.
  11. Vermeulen LC, Windisch PA, Rydman RJ, Bruskiewitz RH, Brixner DI, Vlasses PH (2000). Using a multihospital systems framework to evaluate and establish drug use policy. J Med Syst, 24(4), 235-46. (Read full article)
  12. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley RL (1998). Cytotoxicity uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res, 48((6)), 1481-8.


  1. Stanford J, Martin J, Gibson M, Birdsall E, Brixner DI (In Press). Use of Clomiphene Citrate in the University of Utah Community Clinics [Abstract]. The Journal of Reproductive Medicine. (Epub ahead of print)


  1. Sivam G, Reed MW, Srinivasan A, Morgan AC, Brixner DI, Vrudhula VM, Comezoglu FT (1996). Targeting Substance - Diagnostic - Therapeutic Agent Conjugates Having Schiff Base Linkages. U.S. Patent No. 5549883. Washington, D.C.:U.S. Patent and Trademark Office.